Different HER2 Protein Expression Profiles Aid in the Histologic Differential Diagnosis Between Urothelial Carcinoma In Situ (CIS) and Non-CIS Conditions (Dysplasia and Reactive Atypia) of the Urinary Bladder Mucosa
We evaluated HER2 expression profiles in 32 carcinoma in situ (CIS) and 31 non-CIS conditions (5 dysplasia and 26 reactive atypia) of the urinary bladder mucosa by applying breast cancer scoring rules. In situ hybridization was performed on tissue microarrays to assess HER2 gene amplification status...
Gespeichert in:
| Veröffentlicht in: | American journal of clinical pathology 2011-12, Vol.136 (6), p.881-888 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 888 |
|---|---|
| container_issue | 6 |
| container_start_page | 881 |
| container_title | American journal of clinical pathology |
| container_volume | 136 |
| creator | GUNIA, Sven KOCH, Stefan HAKENBERG, Oliver W MAY, Matthias KAKIES, Christoph ERBERSDOBLER, Andreas |
| description | We evaluated HER2 expression profiles in 32 carcinoma in situ (CIS) and 31 non-CIS conditions (5 dysplasia and 26 reactive atypia) of the urinary bladder mucosa by applying breast cancer scoring rules. In situ hybridization was performed on tissue microarrays to assess HER2 gene amplification status. Our immunoprofiling data disclosed moderate to strong HER2 expression in CIS, including the basal layer of the urothelium, and absent to weak HER2 expression in non-CIS conditions. From the histologic differential diagnostic standpoint, immunostaining for HER2 protein represents a useful adjunct to aid in the delineation between CIS and non-CIS conditions of the bladder mucosa. Pathogenically, aberrant HER2 protein expression in CIS seems to be more commonly associated with polysomy than with gene amplification. From a therapeutic viewpoint, prospective clinical studies should investigate the potential benefit of HER2-targeted therapies in CIS, particularly in cases unresponsive to conventional therapeutic regimens. |
| doi_str_mv | 10.1309/AJCPKUZ69LXZGFEA |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_905670598</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>905670598</sourcerecordid><originalsourceid>FETCH-LOGICAL-c397t-237f57a2e3a66688f8146f6727a478f99451cafb1c4ffb2070b8f1578e7f49cd3</originalsourceid><addsrcrecordid>eNpdkU1v1DAQhiMEokvhzglZSBXtIeCPJLaPabrtLixQtayEeom8jt26ytrBdoD9pfwdvO1SpJ5GM_PMOzN6s-w1gu8RgfxD_bE5_7S8qvji-9XZ6bR-kk0QL0hOKcZPswmEEOccUbKXvQjhFkKEGSyeZ3sYQ14SSibZnxOjtfLKRjCbXmBw7l1UxoLp78GrEIyz25I2vQqgNh1IrXijwMyE6Hp3bSR4EDCiT4m4ti6YAI5V_KWUBcskeKP6bbMRXhrr1gLMLbg0cQSHzfzyCAjbgS_O5ikBjbOdiWltAIcnmzD0IhhxR1woIaP5qUAdN4MRR8Dpu1OW3ljhN-C4F12nPPg8ShfEy-yZFn1Qr3ZxP1ueTr81s3zx9Wze1ItcEk5jjgnVJRVYEVFVFWOaoaLSFcVUFJRpzosSSaFXSBZarzCkcMU0KilTVBdcdmQ_e3evO3j3Y1QhtmsTpOp7YZUbQ8thWVFYcpbIt4_IWzd6m45rOa5YyVhBEwTvIeldCF7pdvBmnd5rEWy3lrePLU8jb3a642qtuoeBfx4n4GAHiCBFr72w0oT_XEF5RRgifwFUgrac</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>926858847</pqid></control><display><type>article</type><title>Different HER2 Protein Expression Profiles Aid in the Histologic Differential Diagnosis Between Urothelial Carcinoma In Situ (CIS) and Non-CIS Conditions (Dysplasia and Reactive Atypia) of the Urinary Bladder Mucosa</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>GUNIA, Sven ; KOCH, Stefan ; HAKENBERG, Oliver W ; MAY, Matthias ; KAKIES, Christoph ; ERBERSDOBLER, Andreas</creator><creatorcontrib>GUNIA, Sven ; KOCH, Stefan ; HAKENBERG, Oliver W ; MAY, Matthias ; KAKIES, Christoph ; ERBERSDOBLER, Andreas</creatorcontrib><description>We evaluated HER2 expression profiles in 32 carcinoma in situ (CIS) and 31 non-CIS conditions (5 dysplasia and 26 reactive atypia) of the urinary bladder mucosa by applying breast cancer scoring rules. In situ hybridization was performed on tissue microarrays to assess HER2 gene amplification status. Our immunoprofiling data disclosed moderate to strong HER2 expression in CIS, including the basal layer of the urothelium, and absent to weak HER2 expression in non-CIS conditions. From the histologic differential diagnostic standpoint, immunostaining for HER2 protein represents a useful adjunct to aid in the delineation between CIS and non-CIS conditions of the bladder mucosa. Pathogenically, aberrant HER2 protein expression in CIS seems to be more commonly associated with polysomy than with gene amplification. From a therapeutic viewpoint, prospective clinical studies should investigate the potential benefit of HER2-targeted therapies in CIS, particularly in cases unresponsive to conventional therapeutic regimens.</description><identifier>ISSN: 0002-9173</identifier><identifier>EISSN: 1943-7722</identifier><identifier>DOI: 10.1309/AJCPKUZ69LXZGFEA</identifier><identifier>PMID: 22095373</identifier><identifier>CODEN: AJCPAI</identifier><language>eng</language><publisher>Chicago, IL: American Society of Clinical Pathologists</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Carcinoma in Situ - diagnosis ; Carcinoma in Situ - pathology ; Diagnosis, Differential ; Female ; Gene Expression Profiling ; Humans ; Investigative techniques, diagnostic techniques (general aspects) ; Male ; Medical sciences ; Middle Aged ; Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques ; Receptor, ErbB-2 - biosynthesis ; Receptor, ErbB-2 - genetics ; Retrospective Studies ; Urinary Bladder - metabolism ; Urinary Bladder Neoplasms - diagnosis ; Urinary Bladder Neoplasms - genetics ; Urinary Bladder Neoplasms - pathology ; Urothelium - metabolism ; Urothelium - pathology</subject><ispartof>American journal of clinical pathology, 2011-12, Vol.136 (6), p.881-888</ispartof><rights>2015 INIST-CNRS</rights><rights>Copyright American Society for Clinical Pathology Dec 2011</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c397t-237f57a2e3a66688f8146f6727a478f99451cafb1c4ffb2070b8f1578e7f49cd3</citedby><cites>FETCH-LOGICAL-c397t-237f57a2e3a66688f8146f6727a478f99451cafb1c4ffb2070b8f1578e7f49cd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24796381$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22095373$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>GUNIA, Sven</creatorcontrib><creatorcontrib>KOCH, Stefan</creatorcontrib><creatorcontrib>HAKENBERG, Oliver W</creatorcontrib><creatorcontrib>MAY, Matthias</creatorcontrib><creatorcontrib>KAKIES, Christoph</creatorcontrib><creatorcontrib>ERBERSDOBLER, Andreas</creatorcontrib><title>Different HER2 Protein Expression Profiles Aid in the Histologic Differential Diagnosis Between Urothelial Carcinoma In Situ (CIS) and Non-CIS Conditions (Dysplasia and Reactive Atypia) of the Urinary Bladder Mucosa</title><title>American journal of clinical pathology</title><addtitle>Am J Clin Pathol</addtitle><description>We evaluated HER2 expression profiles in 32 carcinoma in situ (CIS) and 31 non-CIS conditions (5 dysplasia and 26 reactive atypia) of the urinary bladder mucosa by applying breast cancer scoring rules. In situ hybridization was performed on tissue microarrays to assess HER2 gene amplification status. Our immunoprofiling data disclosed moderate to strong HER2 expression in CIS, including the basal layer of the urothelium, and absent to weak HER2 expression in non-CIS conditions. From the histologic differential diagnostic standpoint, immunostaining for HER2 protein represents a useful adjunct to aid in the delineation between CIS and non-CIS conditions of the bladder mucosa. Pathogenically, aberrant HER2 protein expression in CIS seems to be more commonly associated with polysomy than with gene amplification. From a therapeutic viewpoint, prospective clinical studies should investigate the potential benefit of HER2-targeted therapies in CIS, particularly in cases unresponsive to conventional therapeutic regimens.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Carcinoma in Situ - diagnosis</subject><subject>Carcinoma in Situ - pathology</subject><subject>Diagnosis, Differential</subject><subject>Female</subject><subject>Gene Expression Profiling</subject><subject>Humans</subject><subject>Investigative techniques, diagnostic techniques (general aspects)</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques</subject><subject>Receptor, ErbB-2 - biosynthesis</subject><subject>Receptor, ErbB-2 - genetics</subject><subject>Retrospective Studies</subject><subject>Urinary Bladder - metabolism</subject><subject>Urinary Bladder Neoplasms - diagnosis</subject><subject>Urinary Bladder Neoplasms - genetics</subject><subject>Urinary Bladder Neoplasms - pathology</subject><subject>Urothelium - metabolism</subject><subject>Urothelium - pathology</subject><issn>0002-9173</issn><issn>1943-7722</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNpdkU1v1DAQhiMEokvhzglZSBXtIeCPJLaPabrtLixQtayEeom8jt26ytrBdoD9pfwdvO1SpJ5GM_PMOzN6s-w1gu8RgfxD_bE5_7S8qvji-9XZ6bR-kk0QL0hOKcZPswmEEOccUbKXvQjhFkKEGSyeZ3sYQ14SSibZnxOjtfLKRjCbXmBw7l1UxoLp78GrEIyz25I2vQqgNh1IrXijwMyE6Hp3bSR4EDCiT4m4ti6YAI5V_KWUBcskeKP6bbMRXhrr1gLMLbg0cQSHzfzyCAjbgS_O5ikBjbOdiWltAIcnmzD0IhhxR1woIaP5qUAdN4MRR8Dpu1OW3ljhN-C4F12nPPg8ShfEy-yZFn1Qr3ZxP1ueTr81s3zx9Wze1ItcEk5jjgnVJRVYEVFVFWOaoaLSFcVUFJRpzosSSaFXSBZarzCkcMU0KilTVBdcdmQ_e3evO3j3Y1QhtmsTpOp7YZUbQ8thWVFYcpbIt4_IWzd6m45rOa5YyVhBEwTvIeldCF7pdvBmnd5rEWy3lrePLU8jb3a642qtuoeBfx4n4GAHiCBFr72w0oT_XEF5RRgifwFUgrac</recordid><startdate>20111201</startdate><enddate>20111201</enddate><creator>GUNIA, Sven</creator><creator>KOCH, Stefan</creator><creator>HAKENBERG, Oliver W</creator><creator>MAY, Matthias</creator><creator>KAKIES, Christoph</creator><creator>ERBERSDOBLER, Andreas</creator><general>American Society of Clinical Pathologists</general><general>Oxford University Press</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20111201</creationdate><title>Different HER2 Protein Expression Profiles Aid in the Histologic Differential Diagnosis Between Urothelial Carcinoma In Situ (CIS) and Non-CIS Conditions (Dysplasia and Reactive Atypia) of the Urinary Bladder Mucosa</title><author>GUNIA, Sven ; KOCH, Stefan ; HAKENBERG, Oliver W ; MAY, Matthias ; KAKIES, Christoph ; ERBERSDOBLER, Andreas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c397t-237f57a2e3a66688f8146f6727a478f99451cafb1c4ffb2070b8f1578e7f49cd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Carcinoma in Situ - diagnosis</topic><topic>Carcinoma in Situ - pathology</topic><topic>Diagnosis, Differential</topic><topic>Female</topic><topic>Gene Expression Profiling</topic><topic>Humans</topic><topic>Investigative techniques, diagnostic techniques (general aspects)</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques</topic><topic>Receptor, ErbB-2 - biosynthesis</topic><topic>Receptor, ErbB-2 - genetics</topic><topic>Retrospective Studies</topic><topic>Urinary Bladder - metabolism</topic><topic>Urinary Bladder Neoplasms - diagnosis</topic><topic>Urinary Bladder Neoplasms - genetics</topic><topic>Urinary Bladder Neoplasms - pathology</topic><topic>Urothelium - metabolism</topic><topic>Urothelium - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>GUNIA, Sven</creatorcontrib><creatorcontrib>KOCH, Stefan</creatorcontrib><creatorcontrib>HAKENBERG, Oliver W</creatorcontrib><creatorcontrib>MAY, Matthias</creatorcontrib><creatorcontrib>KAKIES, Christoph</creatorcontrib><creatorcontrib>ERBERSDOBLER, Andreas</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of clinical pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>GUNIA, Sven</au><au>KOCH, Stefan</au><au>HAKENBERG, Oliver W</au><au>MAY, Matthias</au><au>KAKIES, Christoph</au><au>ERBERSDOBLER, Andreas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Different HER2 Protein Expression Profiles Aid in the Histologic Differential Diagnosis Between Urothelial Carcinoma In Situ (CIS) and Non-CIS Conditions (Dysplasia and Reactive Atypia) of the Urinary Bladder Mucosa</atitle><jtitle>American journal of clinical pathology</jtitle><addtitle>Am J Clin Pathol</addtitle><date>2011-12-01</date><risdate>2011</risdate><volume>136</volume><issue>6</issue><spage>881</spage><epage>888</epage><pages>881-888</pages><issn>0002-9173</issn><eissn>1943-7722</eissn><coden>AJCPAI</coden><abstract>We evaluated HER2 expression profiles in 32 carcinoma in situ (CIS) and 31 non-CIS conditions (5 dysplasia and 26 reactive atypia) of the urinary bladder mucosa by applying breast cancer scoring rules. In situ hybridization was performed on tissue microarrays to assess HER2 gene amplification status. Our immunoprofiling data disclosed moderate to strong HER2 expression in CIS, including the basal layer of the urothelium, and absent to weak HER2 expression in non-CIS conditions. From the histologic differential diagnostic standpoint, immunostaining for HER2 protein represents a useful adjunct to aid in the delineation between CIS and non-CIS conditions of the bladder mucosa. Pathogenically, aberrant HER2 protein expression in CIS seems to be more commonly associated with polysomy than with gene amplification. From a therapeutic viewpoint, prospective clinical studies should investigate the potential benefit of HER2-targeted therapies in CIS, particularly in cases unresponsive to conventional therapeutic regimens.</abstract><cop>Chicago, IL</cop><pub>American Society of Clinical Pathologists</pub><pmid>22095373</pmid><doi>10.1309/AJCPKUZ69LXZGFEA</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9173 |
| ispartof | American journal of clinical pathology, 2011-12, Vol.136 (6), p.881-888 |
| issn | 0002-9173 1943-7722 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_905670598 |
| source | MEDLINE; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals |
| subjects | Adult Aged Aged, 80 and over Biological and medical sciences Carcinoma in Situ - diagnosis Carcinoma in Situ - pathology Diagnosis, Differential Female Gene Expression Profiling Humans Investigative techniques, diagnostic techniques (general aspects) Male Medical sciences Middle Aged Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques Receptor, ErbB-2 - biosynthesis Receptor, ErbB-2 - genetics Retrospective Studies Urinary Bladder - metabolism Urinary Bladder Neoplasms - diagnosis Urinary Bladder Neoplasms - genetics Urinary Bladder Neoplasms - pathology Urothelium - metabolism Urothelium - pathology |
| title | Different HER2 Protein Expression Profiles Aid in the Histologic Differential Diagnosis Between Urothelial Carcinoma In Situ (CIS) and Non-CIS Conditions (Dysplasia and Reactive Atypia) of the Urinary Bladder Mucosa |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T15%3A04%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Different%20HER2%20Protein%20Expression%20Profiles%20Aid%20in%20the%20Histologic%20Differential%20Diagnosis%20Between%20Urothelial%20Carcinoma%20In%20Situ%20(CIS)%20and%20Non-CIS%20Conditions%20(Dysplasia%20and%20Reactive%20Atypia)%20of%20the%20Urinary%20Bladder%20Mucosa&rft.jtitle=American%20journal%20of%20clinical%20pathology&rft.au=GUNIA,%20Sven&rft.date=2011-12-01&rft.volume=136&rft.issue=6&rft.spage=881&rft.epage=888&rft.pages=881-888&rft.issn=0002-9173&rft.eissn=1943-7722&rft.coden=AJCPAI&rft_id=info:doi/10.1309/AJCPKUZ69LXZGFEA&rft_dat=%3Cproquest_cross%3E905670598%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=926858847&rft_id=info:pmid/22095373&rfr_iscdi=true |